Encorafenib is under clinical development by Pfizer and currently in Phase III for Melanoma. According to GlobalData, Phase III drugs for Melanoma have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Encorafenib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Encorafenib (Braftovi) acts as anti-neoplastic agent. It is formulated as hard gelatin capsules for oral route of administration. Braftovi is indicated in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test and treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation.
Encorafenib (LGX-818) is under development for the treatment of melanoma and non-small cell lung cancer, metastatic thyroid cancerar, advanced BRAF mutant metastatic colorectal cancer and metastatic BRAF (gene) mutant melanoma, refractory and relapsed multiple myeloma. It was also under development for the treatment of non-small cell lung cancer, thyroid cancer, brain metastases and hematological malignancies.
Pfizer discovers, develops, manufactures and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, cancer, inflammation, immune disorders and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US.
For a complete picture of Encorafenib’s drug-specific PTSR and LoA scores, buy the report here.